| abstract |
The present invention relates to a protein comprising a serine protease inhibitory peptide, such as but not limited to Kunitz domain peptides, including but not limited to fragments and variants thereof, fused to albumin. Such fusion proteins are collectively referred to herein as "albumin fusion proteins of the invention". Such fusion proteins exhibit prolonged shelf life and / or prolonged therapeutic activity in solution. The present invention includes therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, combinations, and kits. The invention also relates to a nucleic acid molecule encoding an albumin fusion protein of the invention, as well as to a vector containing such nucleic acid, such nucleic acid and host cells transformed with the vector, and using such nucleic acid, vector, and / or host cell. It includes a method for producing an albumin fusion protein of. The invention also relates to compositions and methods for inhibiting Neutrophil Elastase, Kallikrein, and Plasmin. The invention also relates to compositions and methods for treating cystic fibrosis and cancer. |